Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination Therapies with Anti-CD38 Antibodies

an anti-cd38 and anti-cd38 technology, applied in the direction of antibody medical ingredients, drug compositions, peptides, etc., can solve the problems of no evidence of a cure, only a small overall survival, and multiple tumors and lesions throughout the skeletal system

Inactive Publication Date: 2016-03-10
JANSSEN BIOTECH INC
View PDF6 Cites 29 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about a method of treating a type of cancer that affects the blood. The method involves giving a patient a special antibody that targets a protein called CD38, which is associated with the cancer. The antibody can kill these cancer cells on its own or by helping other cells in the body to do so. The method also involves giving the patient a substance called all-trans retinoic acid, which can further boost the effectiveness of the antibody treatment. This combination therapy could be effective in treating patients with CD38-positive hematological malignancies.

Problems solved by technology

The disease ultimately attacks bones and bone marrow, resulting in multiple tumors and lesions throughout the skeletal system.
Recent advances using high dose chemotherapy followed by autologous bone marrow or peripheral blood mononuclear cell transplantation have increased the complete remission rate and remission duration, yet overall survival has only been slightly prolonged, and no evidence for a cure has been obtained.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination Therapies with Anti-CD38 Antibodies
  • Combination Therapies with Anti-CD38 Antibodies
  • Combination Therapies with Anti-CD38 Antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

General Methods

Antibodies and Reagents

[0192]A human mAb against an innocuous antigen (HIV-1 gp120) was used as an isotype control as described previously (van der Veers et al., Haematologica 96:284-290, 2011; van der Veers et al., Blood Cancer J 1:e41, 2011). All-trans retinoic acid (ATRA) was purchased from Sigma-Aldrich and diluted in DMSO.

Bioluminescence Imaging (BLI)-Based ADCC Assays Using Luciferase (LUC)-Transduced MM Cell Lines

[0193]LUC-transduced MM cell lines were co-cultured with effector cells (freshly isolated PBMCs from healthy donors) at an effector to target ratio of 1:25 in white opaque 96-well flat bottom plates (Costar) in the presence of daratumumab (0.001, 0.01, 0.1, and 1.0 μg / mL) for four hours. The survival of LUC+-MM cells was then determined by BLI, 10 minutes after addition of the substrate luciferin (125 μg / mL; Promega). Lysis of MM cells was determined using the following formula: % lysis=1−(mean BLI signal in the presence of effector cells and daratumum...

example 2

ATRA Increases CD38 Expression on MM Cell Lines and in Primary MM Cells

[0198]An increase in CD38 expression levels may enhance the efficacy of daratumumab to kill MM cells via ADCC or CDC. Interaction of ATRA with nuclear retinoic acid receptors results in altered expression of target genes including induction of CD38 expression (Malavasi F. J Leukoc Biol 90:217-219, 2011; Drach et al., Cancer Res 54:1746-1752, 1994). Therefore, effect of ATRA on MM cell lines RPMI8226, UM9, and XG1 was studied. MM cells were incubated with RPMI-1640 medium alone or with ATRA ranging from 0-25 nM for 48 hours (FIG. 1A) or were incubated with 10 nM ATRA for 24, 48, 72 or 96 hours (FIG. 1B) and then harvested to determine CD38 expression by flow cytometry using a FACS-Calibur device (Becton Dickinson) and anti-CD38 antibody (Beckman Coulter). The data were analyzed using the CellQuest software.

[0199]Minimum of 10 nM ATRA was sufficient to induce a 1.9-4.4-fold increase in CD38 expression on the MM cel...

example 3

ATRA-Mediated Upregulation of CD38 Enhances Both Daratumumab-Mediated ADCC and CDC Against MM Cells

[0202]Possible effect of ATRA-induced upregulation of CD38 expression on daratumumab-induced ADCC and CDC was tested in MM cell lines XG-1, RPMI8226 and UM9 and in primary MM cells.

[0203]For MM cell lines, CDC and ADCC were assessed using bioluminescence imaging (BLI) based ADCC and CDC assays as described above. For primary MM cells, CDC and ADCC were assessed using Flow cytometry-based ex vivo ADCC and CDC assays in BM-MNC as described above. In the assays, cells were pre-treated with 10 nM ATRA or solvent control for 48 hours, followed by incubation with or without daratumumab in the presence of PBMCs as effector cells for assessment of ADCC or in the presence of human serum as complement source for analysis of CDC. Isotype control was added at 10 μg / ml, and 10% heat-inactivated serum was used as control for CDC.

[0204]FIG. 3A, FIG. 3B and FIG. 3C show the results of daratumumab-indu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application Ser. No. 62 / 087,287 filed 4 Dec. 2014 and U.S. Provisional Application Ser. No. 62 / 047,877, filed 9 Sep. 2014, the entire contents of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to combination therapies with anti-CD38 antibodies and all-trans retinoic acid.BACKGROUND OF THE INVENTION[0003]B-cell malignancies include B-cell chronic lymphocytic leukemia, mantle cell lymphoma, Burkitt lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma, Hodgkin's lymphoma, hairy cell leukemia, primary effusion lymphoma and AIDS-related Non-Hodgkin's Lymphoma. B-cell malignancies comprise more than 85% of diagnosed lymphomas.[0004]Multiple myeloma (MM) is a B cell malignancy characterized by the latent accumulation of secretory plasma cells in bone marrow with a low proliferative index and an extended life spa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/203A61K39/395C07K16/40
CPCA61K31/203C07K16/40C07K2317/734C07K2317/732A61K39/39558A61P35/00A61K2039/505C07K16/2896C07K2317/34A61K2300/00A61K31/454C07K2317/51C07K2317/56C07K2317/565C07K2317/92
Inventor LOKHORST, HENK M.MUTIS, TUNANIJHOF, INGER SVAN DE DONK, NIELS
Owner JANSSEN BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com